Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Sarcoma 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Neoplasms 1Hemangiosarcoma 1Carcinoma, Intraductal, Noninfiltrating 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × 4-hydroxy-N-desmethyltamoxifen × Clear all
NCT06075953 2026-05-22

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
400 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05607004 2025-10-30

EVANGELINE

Atossa Therapeutics, Inc.

Phase 2 Recruiting
87 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡